Table 1.
Demographic and clinicopathological characteristics of the study population (N=879)
| Category | N (%) |
|---|---|
| Age at diagnosis | |
| Median | 63.0 |
| Min, Max | 30, 90 |
| Age at diagnosis | |
| < 75 | 792 (90.1) |
| ≥ 75 | 87 (9.9) |
| Age at diagnosis | |
| < Median | 402 (45.7) |
| ≥ Median | 477 (54.3) |
| Gender | |
| Male | 562 (63.9) |
| Female | 317 (36.1) |
| Race | |
| Chinese | 878 (99.9) |
| Other | 1 (0.1) |
| Smoking status | |
| Never | 447 (55.8) |
| Former | 209 (26.1) |
| Current | 145 (18.1) |
| ECOG Performance Status | |
| 0-1 | 617 (92.6) |
| ≥ 2 | 49 (7.4) |
| AJCC Stage | |
| IIIB | 225 (25.6) |
| IV | 624 (71.0) |
| Others | 30 (3.4) |
| Histology subtype | |
| Squamous cell carcinoma | 207 (23.5) |
| Adenocarcinoma | 630 (71.7) |
| Others | 42 (4.8) |
| Site | |
| Primary tumor | 584 (66.4) |
| Metastatic lesion | 295 (33.6) |
| Sampling location of metastatic lesion | |
| Lymph node | 134 (15.2) |
| Brain | 58 (6.6) |
| Liver | 9 (1.0) |
| Others | 94 (10.7) |
| Tissue type | |
| Surgical resection | 314 (35.7) |
| Biopsy (Core needle biopsy + Bronchial Biopsy + Pleura Biopsy + EBUS + TBNA) |
511 (58.1) |
| Others | 54 (6.1) |
| ALK status | |
| Rearrangement | 32 (6.0) |
| Wild type | 500 (94.0) |
| EGFR mutation status | |
| Mutant | 210 (43.1) |
| Wild type | 277 (56.9) |
| Joint ALK/EGFR Status | |
| ALK+ or EGFR+ | 190 (45.8) |
| ALK-/EGFR- | 225 (54.2) |
ECOG: Eastern Cooperative Oncology Group; AJCC: American Joint Committee on Cancer; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; EBUS-TBNA: endobronchial ultrasound-guided transbronchial fine needle aspiration